Standard BioTools continues its multi-year shift from a specialized life-science instruments provider toward a broader consolidator role in the tools space. The third quarter of 2026 unfolded during a critical period, with the company preparing to finalize an all-stock merger with Treeline Biosciences and planning the sale of its legacy mass cytometry and microfluidics operations. Against this backdrop, the focus remains on whether the core business can stabilize revenue and improve margins as management repositions the portfolio. The substantial cash position from the Illumina and SomaLogic transactions also positions the company for additional moves, so each earnings release offers insight into both near-term performance and the longer-term strategy.
For the quarter ended September 30, 2026, Standard BioTools posted total revenue of $19.39 million, a modest decline from $19.55 million in the prior-year period yet ahead of the roughly $18.80 million consensus. Product revenue climbed 4% to $14.3 million, supported by an 18% increase in instruments to $6.0 million; consumables eased 4% to $8.3 million, and services and other revenue dropped 12% to $5.1 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Gross margin expanded to 55.9% from 48.5%, helped by a better product mix and reduced warranty expenses. Operating expenses declined 28% to $30.6 million, which contributed to narrowing the net loss from continuing operations to $15.0 million from $31.7 million. A $30.0 million gain related to the termination of Illumina earnout and royalty agreements lifted GAAP net income to $13.48 million, or $0.03 per diluted share, versus a $34.69 million net loss last year.
The quarter came across as a modest operational positive. Revenue exceeded expectations, gross margin expanded meaningfully, and the GAAP profit—though one-time in nature—highlighted the financial benefits of the Illumina-related divestiture. Sentiment, however, continues to center on the pending Treeline merger and the planned exits from the mass cytometry and microfluidics businesses, which will reshape the company’s scale and focus. Given the sizable non-recurring items, investors appear to be weighing the strategic milestones more heavily than the slight year-over-year revenue decline.
The key variable ahead is how cleanly the restructuring roadmap is executed. The all-stock Treeline merger is slated to close in the fourth quarter of 2026, and the divestitures are meant to streamline operations and free up resources. Monitoring the timing, terms, and any associated costs or adjustments will be essential.
On the operating side, sustainability of the gross margin improvement, the balance between instrument placements and recurring revenue streams, and ongoing expense discipline deserve attention. Full-year 2026 revenue guidance of $80 million to $85 million offers a useful benchmark for the remaining businesses during the transition. The enlarged cash and investments balance, bolstered by SomaLogic proceeds, will also stay in focus as management decides how to allocate it toward future deals or integration.
In my own work, I find Tickeron’s AI Screener helpful for quickly filtering stocks by technical patterns, fundamentals, and industry benchmarks. It lets me scan thousands of names with customizable criteria and surface ideas that might otherwise take longer to identify manually. For names like Standard BioTools, adding this layer has become a regular part of reviewing quarterly updates and peer comparisons.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 41 cases where LAB's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 83%.
Following a +10.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where LAB advanced for three days, in 202 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 49 cases where LAB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LAB as a result. In 80 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for LAB turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 50 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
LAB moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for LAB entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 50 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.462) is normal, around the industry mean (4.142). P/E Ratio (2.891) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.300) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. LAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of integrated fluidic circuit systems
Industry MedicalNursingServices